crimeancongo
hemorrhag
viru
cchfv
caus
hemorrhag
fever
high
case
mortal
rate
endem
southeastern
europ
africa
asia
limit
catalog
specif
treatment
highlight
necess
look
addit
therapeut
solut
previou
experi
suggest
cchfv
enter
cell
via
clathrin
depend
pathway
therefor
evalu
potenti
anticchfv
activ
sever
molecul
target
entri
possibl
identifi
two
molecul
chloroquin
chlorpromazin
neutral
viru
yield
reduct
assay
test
vero
cell
two
differ
cchfv
strain
sever
combin
includ
ribavirin
assay
test
potenti
synergist
effect
two
molecul
inhibit
cchfv
depend
viru
cell
line
inhibitori
concentr
ic
valu
chloroquin
chlorpromazin
rang
lm
respect
timeofaddit
studi
demonstr
molecul
direct
effect
cchfv
infect
spread
antivir
activ
two
molecul
still
effect
even
ad
h
postinfect
h
select
index
rang
lead
us
evalu
combin
ribavirin
combin
ribavirin
chloroquin
chlorpromazin
synergist
cchfv
though
low
chlorpromazin
select
index
suggest
need
chemic
improv
present
studi
highlight
chloroquin
main
drug
potenti
drug
repurpos
crimeancongo
hemorrhag
viru
cchfv
envelop
segment
negativestrand
rna
viru
belong
nairoviru
genu
bunyavirida
famili
viru
endem
western
area
former
soviet
union
southeastern
southwestern
europ
eastern
central
asia
bent
et
al
hyalomma
spp
tick
consid
import
vector
human
transmiss
epidemiolog
cchf
human
human
transmiss
document
contact
blood
bodi
fluid
human
infect
cchfv
often
result
sever
hemorrhag
diseas
character
extens
ecchymosi
viscer
bleed
hepat
dysfunct
high
case
mortal
rate
averag
mortal
rate
often
cite
bent
et
al
cchfv
infect
context
current
medic
manag
larg
base
treatment
symptom
current
drug
use
treat
cchfv
infect
ribavirin
ribavirin
antivir
therapi
initi
soon
possibl
effect
tasdelen
fisgin
et
al
howev
still
debat
ribavirin
therapeut
benefici
treatment
soaresweis
et
al
treatment
type
interferon
van
eeden
et
al
corticosteroid
therapi
dokuzoguz
et
al
effici
polyclon
anticchfv
human
immunoglobulin
treatment
vassilenko
et
al
test
without
remov
need
new
antivir
molecul
present
studi
aim
character
vitro
anti
cchfv
efficaci
chloroquin
chlorpromazin
chloroquin
use
prevent
treat
malaria
rolain
et
al
also
shown
chloroquin
broadspectrum
molecul
display
vitro
antivir
activ
rang
http
elsevi
bv
right
reserv
rna
virus
rolain
et
al
mechan
action
chloroquin
multipl
depend
pathogen
like
act
via
endosom
lysosom
golgi
vesicl
ph
increas
savarino
et
al
chlorpromazin
well
known
antipsychot
drug
show
antivir
activ
adenoviru
diaconu
et
al
ebola
viru
bhattacharyya
et
al
coronaviru
de
wild
et
al
mechan
action
chlorpromazin
known
interfer
format
clathrin
coat
pit
inhibit
clathrinmedi
endocytosi
wang
et
al
studi
chloroquin
chlorpromazin
found
inhibit
cchfv
replic
vitro
even
ad
h
post
infect
moreov
two
molecul
combin
ribavirin
synergist
effect
observ
vero
cell
studi
anticchfv
efficaci
two
fdaapprov
drug
investig
ko
mice
model
vero
african
green
monkey
kidney
atcc
hepatocarcinoma
cell
line
cellulonet
cat
lyon
franc
cell
grown
dmem
gibco
life
supplement
inactiv
fetal
calf
serum
fcsi
gibco
life
neaa
gibco
life
penicillinstreptomycin
ps
u
penicillin
ml
u
streptomycinml
gibco
life
work
involv
infecti
virus
carri
biosafeti
level
facil
stock
nigeria
mauritania
cchfv
strain
prepar
vero
cell
titrat
plaqu
format
vero
cell
previous
describ
peyrefitt
et
al
chloroquin
sigma
chlorpromazin
sigma
ribavirin
sigma
dissolv
water
store
mm
stock
solut
use
confluent
cell
monolay
vero
cell
incub
dmem
supplement
fcsi
differ
concentr
molecul
rang
lm
chloroquin
chlorpromazin
cytotox
effect
monitor
h
treatment
cell
viabil
measur
use
cell
prolifer
kit
mtt
roch
accord
manufactur
instruct
cytotox
concentr
cc
chloroquin
chlorpromazin
determin
three
independ
experiment
perform
duplic
select
index
si
correspond
rel
effect
drug
inhibit
viral
replic
compar
induc
cell
death
determin
cchfv
studi
vero
cell
seed
well
plate
bd
falcon
densiti
cell
per
well
overnight
incub
infect
cchfv
strain
carri
moi
final
molecul
concentr
test
rang
lm
cq
lm
cpz
cchfv
inoculum
remov
h
incub
cell
incub
addit
ml
carboxymethylcellulos
cmc
sigmaaldrich
fcsi
solut
molecul
day
viral
titer
determin
describ
peyrefitt
et
al
except
revel
step
true
blue
kpl
reagent
use
instead
dab
test
antivir
effect
chloroquin
chlorpromazin
three
condit
assay
pretreat
h
infect
step
concurr
treatment
viru
infect
step
perman
treatment
viru
infect
step
three
independ
experiment
perform
duplic
inhibitori
concentr
ic
cc
calcul
graphpad
prism
softwar
use
nonlinear
regress
model
antivir
effect
chloroquin
chlorpromazin
cchfv
perform
well
plate
overnight
incub
vero
cell
cell
seed
per
well
infect
use
cchfv
strain
moi
final
molecul
concentr
test
lm
chloroquin
lm
chlorpromazin
molecul
ad
h
viral
adsorpt
step
h
postinfect
pi
supernat
harvest
h
pi
viru
titer
determin
plaqu
reduct
assay
describ
section
four
independ
experiment
perform
triplic
test
chloroquin
chlorpromazin
combin
ribavirin
potenti
synergist
effect
determin
isobologram
combinationindex
method
deriv
medianeffect
principl
chou
talalay
use
compusyn
softwar
data
obtain
viru
growth
inhibitori
experi
use
perform
analysi
vero
cell
seed
well
plate
bd
falcon
densiti
cell
per
well
overnight
incub
cell
infect
use
cchfv
strain
moi
molecul
combin
base
comparison
ic
molecul
combin
perform
constant
ratio
chloroquineribavirin
chlorpromazineribavirin
combin
ratio
appli
molecul
concentr
rang
lm
cq
lm
ribavirin
lm
cpz
combin
ad
concomitantli
cchfv
infect
step
maintain
experi
viral
inoculum
remov
h
cell
incub
addit
ml
carboxymethylcellulos
cmc
sigma
aldrich
fcsi
solut
h
pi
viral
titer
determin
describ
peyrefitt
et
al
except
revel
step
true
blue
kpl
reagent
use
instead
dab
combin
test
compar
three
theoret
fraction
viru
inhibit
valu
fa
ie
correspond
theoret
inhibit
theoret
inhibit
theoret
inhibit
three
independ
experiment
perform
duplic
isobologram
method
graphic
represent
pharmacolog
interact
among
molecul
combin
given
valu
shown
theoret
addit
effect
line
repres
graph
three
segment
link
ic
ic
ic
two
molecul
consid
synerg
molecul
wherea
valu
threshold
consid
antagonist
molecul
chloroquin
found
reduc
amount
cchfv
infecti
particl
releas
infect
cell
dose
depend
manner
display
ic
lm
fig
tabl
interestingli
chloroquin
efficaci
confirm
use
anoth
cchfv
strain
show
ic
lm
antivir
effect
also
observ
chlorpromazin
use
two
cchfv
strain
higher
inhibit
efficaci
observ
use
chlorpromazin
compar
chloroquin
ic
rang
lm
fig
howev
due
weaker
cytotox
effect
chloroquin
rel
efficaci
si
appear
higher
chlorpromazin
one
tabl
liver
key
target
organ
cchfv
chloroquin
chlorpromazin
efficaci
also
evalu
use
hepatocyt
infect
cell
cchfv
strain
chloroquin
ic
lm
close
one
show
vero
fig
tabl
interestingli
chlorpromazin
efficaci
stronger
vero
cell
fig
tabl
perman
treatment
either
chloroquin
chlorpromazin
highlight
efficaci
two
inhibitor
investig
antivir
activ
chloroquin
chlorpromazin
ad
pretreat
concurr
cchfv
infect
chloroquin
efficaci
similar
concurr
perman
condit
tabl
pretreat
shown
improv
chloroquin
efficaci
similar
observ
obtain
use
chlorpromazin
tabl
chloroquin
chlorpromazin
ad
sever
time
post
infect
ie
h
pi
concentr
close
ic
obtain
perman
treatment
condit
h
pi
cchfv
titer
reduc
log
chloroquin
ad
h
pi
fig
reduc
log
chlorpromazin
ad
h
pi
fig
h
pi
cchfv
titer
still
reduc
chloroquin
ad
h
pi
log
reduct
chlorpromazin
ad
h
pi
log
reduct
ribavirin
chloroquin
chlorpromazin
describ
distinct
mode
action
wonder
whether
combin
molecul
might
improv
antivir
activ
perform
assay
vero
cell
infect
cchfv
subsequ
treat
ribavirin
combin
either
chloroquin
chlorpromazin
constant
concentr
ratio
chou
talalay
fig
vitro
determin
ic
plaqu
reduct
assay
inhibitori
concentr
ic
chloroquin
chlorpromazin
determin
duplic
well
plate
monolay
vero
b
c
cell
two
cchfv
strain
use
strain
circl
strain
triangl
plaqu
enumer
immunostain
dose
respons
curv
sigmoid
log
inhibitor
vs
respons
curv
perform
use
graphpad
prism
graphpad
softwar
wwwgraphpadcom
shown
fig
vero
cell
treat
cqribavirin
combin
observ
cchfv
inhibit
valu
addit
theoret
line
therefor
signific
synergist
antivir
activ
observ
chloroquin
molecul
combin
ribavirin
similar
result
obtain
use
ribavirinchlorpromazin
combin
fig
worldwid
circul
cchfv
mainli
countri
south
parallel
north
estradapena
et
al
togeth
cchfv
human
case
number
increas
turkey
inc
et
al
lack
effici
specif
treatment
emphas
need
new
antivir
molecul
develop
despit
high
mortal
rate
current
medic
manag
larg
support
ribavirin
antivir
treatment
implement
cchf
still
debat
soaresweis
et
al
strategi
reduc
time
drug
develop
could
recycl
use
exist
drug
condit
work
took
advantag
cchfv
entri
pathway
discoveri
simon
et
al
garrison
et
al
investig
anti
cchfv
activ
approv
molecul
known
inhibit
endocyt
pathway
initi
vitro
antivir
test
data
shown
identifi
antivir
effect
two
molecul
known
inhibit
clathrinph
depend
endocyt
pathway
result
present
vitro
studi
show
chloroquin
chlorpromazin
effect
antivir
molecul
cchfv
ic
chloroquin
chlorpromazin
inhibit
cchfv
lm
respect
chloroquin
found
select
cchfv
inhibitor
select
index
chloroquin
weak
base
known
affect
acid
vesicl
lead
dysfunct
sever
enzym
includ
acid
hydrolas
inhibit
posttransl
modif
randolph
et
al
therefor
potenti
affect
phdepend
entri
virus
gonzalezdunia
et
al
chloroquin
use
mani
year
treatment
malaria
long
term
prophylaxi
inflammatori
diseas
ocular
toxic
kazi
et
al
cardiotox
et
al
oral
mucosa
hyperpigment
de
andrad
et
al
known
complic
long
term
use
chloroquin
revers
side
effect
observ
mucos
pigment
month
discontinu
chloroquin
treatment
armor
et
al
cardiomyopathi
side
effect
lessen
cessat
chloroquin
treatment
prescript
combin
therapi
candesartan
carvedilol
treatment
lopezruiz
urib
contrari
hyperpigment
cardiomyopathi
retinopathi
irrevers
side
effect
long
term
chloroquin
treatment
appear
even
usag
chloroquin
stop
kazi
et
al
nevertheless
daili
dose
chloroquin
seem
relev
develop
ocular
side
effect
risk
retinopathi
lower
dose
exceed
mgkgday
lerman
et
al
minim
daili
dose
exceed
mg
armor
et
al
previous
chloroquin
propos
use
sever
viral
infect
rolain
et
al
antivir
efficaci
molecul
shown
differ
cell
cultur
ic
relat
pathogen
chloroquin
shown
inhibit
chikungunya
viru
ic
lm
khan
et
al
dengu
viru
faria
et
al
coronaviru
ic
lm
keyaert
et
al
merscov
ic
lm
de
wild
et
al
influenza
viru
ic
lm
ooi
et
al
henipaviru
ic
lm
porotto
et
al
chloroquin
also
use
inhibit
hiv
lineag
monocyt
lymphocyt
sperber
et
al
known
hiv
target
cell
adult
mgkg
cq
oral
dose
follow
ngml
plasma
peak
concentr
walker
et
al
close
chloroquin
ic
moreov
chloroquin
known
accumul
cchfv
target
organ
liver
spleen
ipc
inchem
studi
similar
chloroquin
si
assess
two
permiss
cell
vero
human
target
cell
chloroquin
post
infect
addit
ineffici
influenza
virus
di
trani
et
al
effici
h
post
chikv
infect
khan
et
al
way
cchfv
titer
still
reduc
chloroquin
ad
h
pi
suggest
chloroquin
block
post
entri
step
cchfv
replic
cycl
case
rapid
elev
endosom
ph
abrog
viru
endosom
fusion
might
primari
mechan
viru
infect
inhibit
chloroquin
pool
ohkuma
abolish
releas
sialyltransferas
transgolgi
network
acidif
could
account
anoth
inhibitori
mechan
berger
et
al
plasma
chloroquin
concentr
might
influenc
molecul
dosag
mgkg
first
dose
rapidli
detect
plasma
peak
concentr
ngml
walker
et
al
chloroquin
accumul
cchfv
organ
target
liver
spleen
second
molecul
test
chlorpromazin
approv
psychot
drug
describ
other
inhibit
clathrin
depend
pathway
reduc
number
coat
pitsassoci
receptor
cell
surfac
wang
et
al
chlorpromazin
associ
pigment
oral
mucosa
seymour
rudralingham
hepatotox
human
character
elev
serum
alkalin
phosphatas
biliari
cirrhosi
main
chlorpromazin
side
effect
gandhi
et
al
hyperglycaemia
hypothermia
also
side
effect
relat
chlorpromazin
treatment
bonaccorsi
et
al
record
chlorpromazin
use
antivir
molecul
associ
adenoviru
diaconu
et
al
ebola
viru
bhattacharyya
et
al
recent
coronaviru
treatment
de
wild
et
al
depend
chlorpromazin
posolog
plasma
concentr
reach
ngml
treat
patient
riveracalimlim
et
al
studi
chlorpromazin
inhibitori
effect
observ
treatment
condit
interestingli
chlorpromazin
exhibit
mark
inhibitori
effect
cell
line
whose
pathway
miss
strongli
suggest
involv
clathrin
mediat
endocytosi
blanchard
et
al
cchfv
titer
still
markedli
reduc
chlorpromazin
ad
h
pi
suggest
anoth
post
entri
inhibitori
effect
like
assembl
bud
alreadi
identifi
sindbi
vesicular
stomat
viru
schlesing
cahil
howev
low
chlorpromazin
select
index
diminish
potenti
use
clinic
particularli
drug
use
alon
ribavirin
chloroquin
chlorpromazin
combin
assay
demonstr
synergist
effect
test
condit
expect
ribavirin
chloroquin
chlorpromazin
differ
antivir
mechan
thu
experi
suggest
combinatori
treatment
could
repres
strategi
control
cchfv
infect
promis
vitro
result
confirm
drug
efficaci
evalu
anim
model
sinc
two
mice
model
ifnar
use
assess
ribavirin
effect
cchfv
infect
bereczki
et
al
bent
et
al
observ
effect
surviv
mice
ifnar
mice
oestereich
et
al
howev
oestereich
et
al
demonstr
ribavirin
abl
prevent
lethal
pathophysiolog
cascad
oestereich
et
al
would
relev
investig
near
futur
molecul
compar
other
protect
assay
alon
combin
ribavirin
use
ko
mous
model
